dc.contributor.author | Miguélez Palomo, Cristina | |
dc.contributor.author | De Deurwaerdère, Philippe | |
dc.contributor.author | Sgambato, Veronique | |
dc.date.accessioned | 2021-03-04T09:34:22Z | |
dc.date.available | 2021-03-04T09:34:22Z | |
dc.date.issued | 2020-09-11 | |
dc.identifier.citation | Frontiers In Pharmacology 11 : (2020) // Article ID 593822 | es_ES |
dc.identifier.issn | 1663-9812 | |
dc.identifier.uri | http://hdl.handle.net/10810/50466 | |
dc.description.abstract | The dopaminergic system has been the main focus for almost 70 years and dopaminergic-based strategies still remain the best symptomatic medication to improve quality of life of parkinsonian patients. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | L-Dopa | es_ES |
dc.subject | serotonin | es_ES |
dc.subject | sleep | es_ES |
dc.subject | noradrenaline | es_ES |
dc.subject | GABA | es_ES |
dc.subject | non-motor symptoms | es_ES |
dc.subject | orphan receptor | es_ES |
dc.subject | prodromal Parkinson disease | es_ES |
dc.title | Editorial: Non-Dopaminergic Systems in Parkinson's Disease | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fphar.2020.593822/full | es_ES |
dc.identifier.doi | 10.3389/fphar.2020.593822 | |
dc.departamentoes | Farmacología | es_ES |
dc.departamentoeu | Farmakologia | es_ES |